Key Performance
More- Earnings Score: N/A
- Momentum Score: 14
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
The head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a CAGR of 10.5% from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the highest revenue. Multiple companies are advancing innovative therapies targeting HPV16-positive HNSCC and other molecular pathways.
07/13/2026, 1:00 PM • GlobeNewswire
Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against Graphic Packaging Holding Company, Immutep Limited, and Phreesia, Inc. The lawsuits allege materially false statements and/or failure to disclose material facts regarding inventory management, clinical trial status, and long-term growth outlook respectively. Investors who purchased shares during specified periods and suffered losses are encouraged to seek lead plaintiff status by the July 6-13, 2026 deadlines.
07/01/2026, 7:00 AM • GlobeNewswire
Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against multiple companies including Graphic Packaging Holding Company, Immutep Limited, and Phreesia, Inc. The lawsuits allege materially false or misleading statements regarding inventory management, clinical trial prospects, and growth outlook respectively. Investors who purchased shares during specified periods and suffered losses are encouraged to seek lead plaintiff status.
06/29/2026, 7:00 AM • GlobeNewswire
A class action lawsuit has been filed against Immutep Limited alleging that company defendants made materially false and misleading statements regarding the TACTI-004 trial's status and prospects. The complaint claims defendants concealed negative clinical data and misrepresented the trial's operational progress and interim futility analysis timing. Investors who purchased Immutep securities between March 24, 2025 and March 12, 2026 are eligible to join the case, with a lead plaintiff deadline of July 6, 2026.
06/14/2026, 12:00 PM • GlobeNewswire
The Schall Law Firm is seeking investors to join a class action lawsuit against Immutep Limited for securities fraud. The company allegedly made false and misleading statements about its TACTI-004 trial results, claiming 'strong operational progress' while knowing the trial would fail to meet its primary efficacy endpoints. Investors who purchased securities between March 24, 2025 and March 12, 2026 are encouraged to participate.
06/12/2026, 9:00 AM • GlobeNewswire
Immutep Limited (IMMP) stockholders who purchased ADRs between March 24, 2025 and March 12, 2026 have until July 6, 2026 to seek lead plaintiff appointment in a securities class action. The lawsuit follows an 83% single-day stock decline after the company disclosed on March 13, 2026 that an Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III trial for futility.
06/08/2026, 4:00 PM • GlobeNewswire
Holzer & Holzer, LLC announced lead plaintiff deadlines for multiple shareholder class action lawsuits against companies including Graphic Packaging Holding Company, Immutep Limited, and Phreesia, Inc. The lawsuits allege materially false and misleading statements regarding inventory management, clinical trial prospects, and growth outlook. Investors who purchased shares during specified periods and suffered losses are encouraged to seek lead plaintiff status by the announced deadlines in July 2026.
06/08/2026, 8:00 AM • GlobeNewswire
A class action lawsuit has been filed against Immutep Limited (NASDAQ: IMMP) alleging that company defendants made materially false and misleading statements regarding the TACTI-004 trial's status and prospects. The complaint claims defendants concealed negative clinical data while misrepresenting the trial's operational progress and efficacy prospects. Investors who purchased Immutep securities between March 24, 2025 and March 12, 2026 are eligible to join the case, with a lead plaintiff deadline of July 6, 2026.
06/07/2026, 12:00 PM • GlobeNewswire
Rosen Law Firm is reminding investors who purchased Immutep Ltd. ADRs between March 24, 2025 and March 12, 2026 of an important July 6, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Immutep made false or misleading statements regarding the TACTI004 trial's status and prospects, while possessing internal clinical data suggesting increased risk of the trial failing to meet its efficacy and safety objectives.
06/05/2026, 2:52 PM • GlobeNewswire
A class action lawsuit has been filed against Immutep Limited (IMMP) for allegedly misleading investors about the viability and efficacy of its TACTI-004 drug candidate. The company claimed strong operational progress in January 2026, but in March 2026, an Independent Data Monitoring Committee recommended discontinuing the Phase III trial for futility. The stock price plummeted 83% following the announcement, from $2.76 to $0.48 per share.
06/05/2026, 1:57 PM • GlobeNewswire
Robbins LLP is investigating allegations that LKQ Corporation misled investors regarding its acquisition of Uni-Select Incorporated. The lawsuit claims LKQ falsely represented the acquisition as having minimal integration risk and assured investors the FinishMaster integration was on target, when in reality FinishMaster was losing major customers and market share. The class period spans February 27, 2023 to July 23, 2025.
06/05/2026, 1:51 PM • GlobeNewswire
Immutep announced positive Phase I interim data for IMP761, a first-in-class LAG-3 agonist antibody for autoimmune diseases. The study met its primary endpoint, demonstrating favorable safety and tolerability in healthy volunteers, with statistically significant pharmacodynamic activity at 7 mg/kg dose. The results support further clinical investigation in autoimmune indications such as rheumatoid arthritis.
06/04/2026, 8:00 AM • GlobeNewswire
Rosen Law Firm is soliciting investors who purchased securities of Immutep Ltd., POET Technologies Inc., and DNOW Inc. to join class action lawsuits. The Immutep case alleges the company made false statements about its TACTI-004 trial prospects, concealing material risks of study failure. The deadline to serve as lead plaintiff in the Immutep case is July 6, 2026.
06/02/2026, 6:41 PM • GlobeNewswire
Rosen Law Firm has filed securities class action lawsuits against POET Technologies, Immutep Ltd., and DNOW Inc., alleging material misstatements and omissions. POET Technologies is accused of misrepresenting its tax status as a PFIC and having an executive violate non-disclosure agreements. Investors with losses exceeding $100,000 are encouraged to join the class actions before the June 29, 2026 lead plaintiff deadline.
06/02/2026, 6:09 PM • GlobeNewswire
A securities class action lawsuit has been filed against Immutep Ltd. (NASDAQ: IMMP) for allegedly making false and misleading statements about the TACTI004 trial. The company reportedly concealed negative information about the trial's prospects while publicly stating it was on track, despite internal data suggesting increased risk of failure. Investors who purchased ADRs between March 24, 2025 and March 12, 2026 may be eligible for compensation, with a lead plaintiff deadline of July 6, 2026.
05/30/2026, 7:13 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 07/13/2026
Company Profile
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.